4-amino-5-(4-hydroxyphenyl)-7-isopropylpyrrolo[2,3-d]-pyrimidine | 213744-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-amino-5-(4-hydroxyphenyl)-7-isopropylpyrrolo[2,3-d]-pyrimidine
• 英文别名: 5-(4-Hydroxyphenyl)-7-isopropylpyrrolo[2,3-d]pyrimidin-4-ylamine；4-amino-5-(4-hydroxyphenyl)-7-isopropylpyrrolo-[2,3-d]pyrimidine；4-amino-5-(4-hydroxyphenyl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine；4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenol
• CAS: 213744-90-2
• 化学式: C₁₅H₁₆N₄O
• 分子量: 268.318
• InChiKey: OZSXUVWJCWELFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  77
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-5-(4-hydroxyphenyl)-7-isopropylpyrrolo[2,3-d]-pyrimidine 在 氢氧化钾 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-[4-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenoxy]-benzoic acid
  参考文献：
  名称：

  Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck II

  摘要：

  Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are novel, potent and selective inhibitors of lck in vitro. Exploration of C-6 position of the pyrrolo[2,3-d]pyrimidine and the terminal phenyl group structure-activity relationship (SAR) is detailed. Compound 1 is orally active in animal models. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00442-x
• 作为产物：
  描述：

  4-氯-7-异丙基-7H-吡咯并[2,3-D]嘧啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 ammonium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 0.25h， 生成 4-amino-5-(4-hydroxyphenyl)-7-isopropylpyrrolo[2,3-d]-pyrimidine
  参考文献：
  名称：

  [EN] PROTEIN KINASE INHIBITORS
  [FR] INHIBITEURS DE PROTÉINES KINASES

  摘要：

  本发明涉及一种新型蛋白激酶抑制剂家族，更具体地说，本发明是针对Tec或Src蛋白激酶家族成员的抑制剂。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗蛋白激酶活性参与的增殖性、炎症性、感染性或自身免疫疾病、紊乱或病症中的用途。更具体地说，本发明涉及一种I式化合物。

  公开号：

  WO2015077866A1

文献信息

• 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS
  申请人：——

  公开号：US20030187001A1

  公开（公告）日：2003-10-02

  Chemical compounds having structural formula I 1 and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperpro;iferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

  具有结构式I1的化合物及其生理上可接受的盐是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞高增殖是因素的疾病状态。这些化合物可用于治疗癌症、高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
  申请人：BASF Aktiengesellschaft

  公开号：US06001839A1

  公开（公告）日：1999-12-14

  Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.5-7 cycloalkenyl group or an (optionally substituted phenyl)C.sub.1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula OR.sub.A in which R.sub.A represents H or a C.sub.1-6 alkyl group provided that a group of formula OR.sub.A is not located on the carbon attached to nitrogen; R.sub.2 represents hydrogen, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C.sub.1-6 alkyl group, optionally substituted phenyl or R.sub.4 ; and R.sub.3 represents a group of formula (a) ##STR2## in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO.sub.2, SO.sub.2 NH, a C.sub.1-4 alkylene chain, NHCO, NHCO.sub.2, CONH, NHCONH, CO.sub.2 or S(O).sub.p in which p is 0, 1 or 2, or A is absent and R.sub.5 is attached directly to the phenyl ring; and R.sub.5 represents optionally substituted phenyl and, additionally, when A is absent R.sub.5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R.sub.4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.

  化学式I的化合物包括其药学上可接受的盐，其中R.sub.1代表氢，2-苯基-1,3-二噁烷-5-基，C.sub.1-6烷基，C.sub.3-8环烷基，C.sub.5-7环烯基或（可选择取代的苯基）C.sub.1-6烷基，其中烷基，环烷基和环烯基基团可选择地被一个或多个OR.sub.A的基团取代，其中R.sub.A代表H或C.sub.1-6烷基基团，前提是OR.sub.A的基团不位于连接氮的碳上；R.sub.2代表氢，C.sub.1-6烷基，C.sub.3-8环烷基，卤素，羟基，（可选择取代的苯基）C.sub.1-6烷基，可选择取代的苯基或R.sub.4；R.sub.3代表下列式(a)的基团：其中苯环另外可选择地被取代，A代表NH，O，NHSO.sub.2，SO.sub.2 NH，C.sub.1-4烷基链，NHCO，NHCO.sub.2，CONH，NHCONH，CO.sub.2或S(O).sub.p，其中p为0, 1或2，或A不存在且R.sub.5直接连接到苯环；R.sub.5代表可选择取代的苯基，并且当A不存在时，R.sub.5代表a）可选择地被卤素取代的邻苯二甲酰亚胺基团或b）可选择地被下列之一取代的吡唑基氨基团：羟基或可选择取代的苯基；R.sub.4代表杂环基团；这些化合物用于治疗哺乳动物的增殖性疾病和免疫系统紊乱。还描述了制备这些化合物的过程和含有这些化合物的药物组合物。
• PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0970084B1

  公开（公告）日：2003-06-04
• Protein Kinase Inhibitors
  申请人：Pharmascience Inc.

  公开号：US20170158697A1

  公开（公告）日：2017-06-08

  The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated.
• US6001839A
  申请人：——

  公开号：US6001839A

  公开（公告）日：1999-12-14